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Abstract
Conventional methods of assessing in-vitro antimalarial drug-concentration effect relationships in
field testing of fresh isolates assess each parasite isolate individually. This leads to systematic
overestimation of EC50 values for the most resistant isolates, and thus overestimation of the degree
of resistance. In antimalarial drug-susceptibility studies conducted on the north-western border of
Thailand the overestimation of EC50 for the most resistant isolate ranged from 15% for artesunate
to 43% for mefloquine. If isolates cannot be stored for re-testing, more accurate estimations of the
degree of resistance can be obtained using a Bayesian approach to data analysis which is described
here.
Background
The development of resistance to antimalarial drugs poses
one of the greatest threats to malaria control and is the
main cause of recent increases in malaria morbidity and
mortality. The precise quantitation of resistance is there-
fore of prime importance. Initially the only way of assess-
ing resistance to antimalarials was by inference from
clinical treatment failures. Occasionally these were sup-
ported by measurement of antimalarial drug concentra-
tions in the patients' blood. Once methods of culturing
Plasmodium falciparum became established, in vitro meth-
ods for measuring the effect of the antimalarial drug
directly on malaria parasite were developed [1]. This
allowed resistance (i.e. reduced susceptibility) to be differ-
entiated from poor adherence or unusual pharmacokinet-
ics as the cause of treatment failure.
In in vitro susceptibility tests, blood samples from malaria
patients are obtained and the infecting malaria parasites
are cultured ex-vivo in the presence of stepwise increases
in the concentrations of antimalarial drugs. Some meth-
ods call for adaptation of parasites to culture first, while
others put blood directly from patients into the test sys-
tem. Field testing, where blood is taken and malaria para-
sites are cultured directly in 96-well plastic plates pre-
dosed with antimalarial at different concentrations, is
now widely used. These freshly obtained parasites are usu-
ally not cryo-preserved and so there is only the one oppor-
tunity to assess the parasite drug susceptibility.
Problems with estimating EC50 for resistant isolates
The three most commonly used methods of in vitro sus-
ceptibility testing of malaria parasites are (i) the micro test
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which assesses inhibition of parasite growth to the sch-
izont stage microscopically, (ii) the radioisotope test
which measures uptake of 3H-hypoxanthine, and (iii)
ELISA based methods which measure the production of
lactate dehydrogenase or histidine rich protein by the par-
asite [2,3]. Results of in vitro tests are expressed as the per-
centage parasite growth/viability plotted against the
antimalarial drug concentration (or log concentration) to
give a dose-response (concentration-effect) curve. The
range of drug concentrations used are chosen because they
are thought a priori to reflect the likely range of parasite
susceptibilities and they are usually prepared as serial
doubling dilutions The resulting dose-response curve is
usually sigmoid (Figure 1) and can be described by a
number of parameters: minimum growth/uptake/produc-
tion, maximum growth/uptake/production, the slope,
and importantly the midway point (EC50) describing the
concentration of drug which is required for 50% of the
maximum inhibitory effect in the test system. These vari-
ables can be read directly from the plot, assessed by probit
analysis, or they require fitting of a statistical model to
data and then derivation from the equation of the model.
A commonly used model is the sigmoid Emax model:
E(C) = Emax - (Emax - Emin)Cγ/(Cγ+EC50
γ)
where Emax  is the maximum effect (e.g. minimum
growth), Emin is the minimum effect (maximum growth),
C is the concentration of drug, γ is the slope of the linear
part of the curve, and EC50 is defined as before. Parameter
Emin sometimes is set to 0 to avoid overparameterization.
The most resistant isolate(s), by definition, represents the
extreme value in one tail of a distribution of values. These
values lie at the lower end of the dilution range (Figure 2).
As concentrations are taken usually as serial dilutions,
there are less measurements of drug effect at this end of
range (because most of the concentrations in the test sys-
tem have no effect). The relatively large intervals between
the highest drug concentrations in the test system mean
that often the middle range of inhibitory effect is not
observed at all; for one dilution there may be no (or very
little) drug effect and for the next dilution the maximum
(or close to maximum) effect is measured (Figures 1 to 3).
If the distribution of all EC50 values in the parasite popu-
lation is unimodal (and this is a critical point) then, given
that the EC50 lies at an unknown point between two val-
ues (two dilutions), the prior probability suggests that the
true value lies closer to the median value of the popula-
tion than to the more extreme value.
But the fit, and thus estimated EC50 value, is based only on
the observations for that isolate. It is independent of the
distribution of values from other isolates in the series and,
in case of the sigmoid model, a symmetrical curve is fitted.
The fit is poor but the midpoint value will lie close to half
way between the two concentrations tested (Figure 2).
Standard fitting procedures, therefore, systematically
overestimate EC50 values for the most resistant parasites.
Moreover, when curve fitting is attempted for resistant iso-
lates and only responses close to 100% or 0% are
observed, often either computational problems occur and
the curve cannot be fitted at all, or the curve is fitted but
the standard errors of the estimates are large. In this case,
a priori information about the population could be very
useful in planning the future experiments and deciding
where the EC50 is expected to be and where the concentra-
tions measurements should be taken in order to pinpoint
the 50% response. In this report a Bayesian approach to
the estimation of EC50 in the outlying most resistant iso-
lates together with worked examples from field data is pre-
sented.
Methods
These suggestions apply to field methods of assessing in
vitro susceptibility to malaria parasites where the inhibi-
tory values (EC50, EC90, etc.) are extrapolated from obser-
vations over a preset concentration range. This range is set
based on the earlier experience with field testing. The cri-
teria for "goodness of fit" have not been standardized and,
therefore, vary between investigators. The variation will
affect the results, but this important issue is not discussed
here.
Standard dose-response curve in antimalarial drug suscepti- bility testing (arbitrary units) Figure 1
Standard dose-response curve in antimalarial drug suscepti-
bility testing (arbitrary units). In this case the response or 
effect is inhibition of growth, uptake, or synthesis.
0
25
50
75
100
0 8 16 32 64 128
       Drug concentration
Growth/uptake/production (%)Malaria Journal 2007, 6:4 http://www.malariajournal.com/content/6/1/4
Page 3 of 9
(page number not for citation purposes)
Estimating EC50 based on the population estimates
If, from the in vitro drug susceptibility experiment, it is
known that the EC50 lies in the interval (a to b), where b =
2a if doubling solutions were used, the Bayesian estimate
of EC50 in this interval can be constructed in the following
way:
1. estimate distribution of EC50 values for this batch of iso-
lates (using 'good' estimates coming from 'good' fits). This
involves estimating EC50 for each isolate.
2. using distribution of EC50, calculate median value of
EC50 in the interval (a,b)
3. this summary measure value is the Bayesian estimate of
EC50 in the interval (a,b).
Characterization of the distribution of EC50  values is
required, and this is not always possible, but if the EC50
values can be shown to have a normal or lognormal dis-
tribution or can be transformed to normal using Box-Cox
transformation [4], then the estimation of the corrected
EC50 value can be done using a pocket calculator, as
described below. The corrections suggested apply to con-
tinuous distributions and are not appropriate for clearly
discontinuous distributions (for example, those seen
where one or more parasite isolates contain the cyto-
Illustrative example of a distribution of antimalarial susceptibility concentration-growth inhibition curves fitted using standard  models Figure 2
Illustrative example of a distribution of antimalarial susceptibility concentration-growth inhibition curves fitted using standard 
models. The most resistant isolate's curve fit is poor as inhibition was obtained only with the highest concentration tested (64 
ng/mL), and so the EC50 derived using standard curve fitting lies at the mid-point (48 ng/mL) between the two highest concen-
trations tested (32 and 64 ng/mL). The Bayesian approach (dotted line) provides a lower estimate closer to the rest of the pop-
ulation.
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chrome b mutations which confer high level atovaquone
resistance in P. falciparum).
Normal distribution
Probability density f(x) of a normally distributed random
variable x is given by the expression
f(x) = 1/(σπ )·exp(-(x-µ)2/2σ2)
where exp(z) = ez, µ is the expectation or mean value of x
and σ is the standard deviation of x.
The median value of x on the interval (a, b) is calculated
(see Appendix II) as:
Median (x) = Φ-1 ((Φ((a-µ)/σ) + Φ((b-µ)/σ))/2)·σ + µ
(1)
where Φ(t) =   dz and z is a standard normal dis-
tribution N(1,0). Values of Φ(z) are tabulated and can be
found in any book with statistical tables.
Lognormal distribution
A random variable y is log-normally distributed if x =
log(y) is normally distributed with log denoting the natu-
ral logarithm. The general formula for the probability
density function of the lognormal distribution is
f(y) = 1/((y-θ)σπ )·exp(-(log(y-θ)/m)2/2σ2)
where σ is the shape parameter, θ is the location parame-
ter and m is the scale parameter (equal to median). The
calculation of the median value in the interval (a,b) may
be performed using the log-transformed data. Firstly, the
median of transformed x needs to be found in interval
2
fz
t
()
−∞ ∫
2
Dose-Response relationship; real data from 3hypoxanthine uptake inhibition in-vitro susceptibility tests for the most resistant  isolates in the series (6) for (A) Artesunate, (B) Halofantrine, (C) Mefloquine, (D) Mefloquine, (E) Chloroquine, (F) Chloro- quine Figure 3
Dose-Response relationship; real data from 3hypoxanthine uptake inhibition in-vitro susceptibility tests for the most resistant 
isolates in the series (6) for (A) Artesunate, (B) Halofantrine, (C) Mefloquine, (D) Mefloquine, (E) Chloroquine, (F) Chloro-
quine.
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(log(a), log(b)). As transformed x is normally distributed,
methods described in the paragraph above apply and
equation (1) can be used. Then the median needs to be
back-transformed (using the exponent function) to the
original scale. Because of monotonic transformation, the
median of transformed x in interval (log(a), log(b)) corre-
sponds to the median of x in the interval (a,b)
Median (x) = exp (Φ-1 ((Φ((log(a)-µ)/σ) + Φ((log(b)-µ)/
σ))/2)·σ + µ)   (2)
Box -Cox family of transformations
The Box-Cox transformation is defined as:
T(y) = (yλ-1)/λ
where y is the random variable and λ is the transforma-
tion parameter. For λ = 0, the natural log of the data is
taken instead of using the above formula. Similarly as
before, if T(y) has an median value m in interval (T(a),
T(b)) then median of y in interval (a,b) is m1/λ.
Simple method using computer simulation
An easier way to obtain the Bayesian estimate of the EC50,
for data where the effect goes from 100% to 0% over a sin-
gle dilution, which does not require any equations, is to
use computer simulations. They can be done in Excel®, or
with any statistical software. Once the distribution of EC50
is established, a large number of points (for example 106)
from this distribution can be readily generated and then
the estimate of the EC50 for a resistant isolate can simply
be found as a median value for all data points which are
in the interval (a,b) between the two dilutions.
Data
The data used to illustrate these issues come from the
Shoklo Malaria Research Unit (SMRU) in Thailand. They
are in-vitro susceptibility data of malaria parasites isolated
from patients recruited in two camps for displaced per-
sons of the Karen ethnic minority situated in an area of
forested hills on the north-western border of Thailand.
Antimalarial drug susceptibility data were obtained using
the hypoxanthine uptake inhibition assay and have been
described and analysed elsewhere [5]. In total, 268 fresh
isolates of P. falciparum from primary infections were
assayed for in vitro drug susceptibilities to a wide range of
antimalarials including chloroquine diphosphate, qui-
nine citrate, mefloquine hydrochloride, halofantrine
hydrochloride, artesunate, dihydroartemisinin, arte-
mether, lumefantrine, and atovaquone. To illustrate this
particular issue we selected data for four drugs; meflo-
quine, chloroquine, halofantrine and artesunate.
Statistical Analysis
For each of the examined drugs, the distribution of EC50
values was estimated in the following way:
1. alll isolates which had at least one inhibitory response
value between 30 and 70% of the maximum response
were identified and selected as this was considered a priori
to be a minimum requirement for the data points to give
stable estimates
2. the Emax model using Stata® software (StataCorp. 2005,
ver 9) was fitted to each of the selected isolates
3. isolates for which the model did not reach convergence
were excluded
4. isolates which had negative estimates of EC50 were
excluded
5. the distribution of EC50 values in the remaining isolates
(N) was examined
6. If possible, EC50 values were transformed (logarithmic
or Box-Cox transformation) to normality. Normality of
the distributions was tested using the Kolmogorov-Smir-
nov test.
For each of the isolates which were most resistant to
mefloquine, halofantrine, chloroquine and artesunate the
EC50 values were estimated using three methods: (a) by
fitting a standard 3-parameter sigmoid curve using Win-
Nonlin® (Pharsight, ver 4.1); (b) by fitting the 3-parameter
sigmoid curve using Gibbs sampling using WinBUGS®; (c)
by the "Bayesian" method based on the population distri-
bution of EC50 values proposed in this paper (equation 1).
The standard sigmoid model (a) was fitted using Nelder-
Mead minimisation, with no specified boundaries for
parameters and WinNonlin® generated starting values. In
the Gibbs sampling estimation (b) the distribution of
EC50 values was estimated as described above, while non-
informative uniform priors with appropriate bounds were
used for other parameters:
Emax ~ uniform(0.5,1.5)
γ ~ uniform(1,100)
The effect of the bounds of parameter γ on estimates of
EC50 were also examined by restricting the upper bound to
30, and then to 50. Parameter estimates were summarized
as median and 95% range of the posterior estimates over
90,000 iterations.Malaria Journal 2007, 6:4 http://www.malariajournal.com/content/6/1/4
Page 6 of 9
(page number not for citation purposes)
Results
The measured responses of isolates most resistant to
mefloquine (two series), halofantrine, chloroquine (two
series) and artesunate are presented in Figure 3.
Table 1 describes estimated distributions of the EC50 val-
ues for each drug. All of them could be assumed to be log-
normally distributed. Overall, after the selection
described in points 1, 3 and 4, about half of the isolates
contributed to the estimation.
Table 2 lists parameter estimates obtained from the Win-
Nonlin analysis (a) for the resistant isolates. Only for
artesunate and chloroquine do the estimates have reason-
able precision, for the other drugs the standard errors
(CV%) are very large. This means that the model does not
estimate the parameters accurately. In fact, when refitting
the model with different starting values, different esti-
mates of EC50 (within ± 10% of the quoted value) were
obtained each time (data not shown). In Table 3, corre-
sponding parameter estimates obtained from fitting the
three-parameter sigmoid curve using the Gibbs sampling
method (b) are listed. Obviously the slope of the concen-
tration-effect relationship is a critical determinant of EC50
but the EC50 estimates were relatively insensitive to these
prior slope estimates (γ); change of the upper bounds for
parameter γ did not affect substantially the estimated val-
ues of parameters whereas slight increases in the EC50 esti-
mates (<10%) were observed with lower bound changes
(Table 4).
Calculation of the Bayesian EC50
Halofantrine
In total 197 isolates were tested, of which 85 satisfied the
criteria (see above, points 1–5). EC50 values estimated in
these samples were found to have a lognormal distribu-
tion (p = 0.100, Kolmogorov-Smirnov test) with mean of
1.84 and standard deviation of 0.979; i.e. log(EC50) ~
N(1.84, 0.979) (Table 1).
From the equation (2) the EC50 was calculated as 41.2 ng/
mL in the highest concentration interval (32.6 – 65.32 ng/
mL).
Artesunate
Of 191 isolates, 89 satisfied the criteria and for them
log(EC50) ~ N(0.75, 0.888), p = 0.074 (Table 1) In the
highest concentration interval (16.73–33.46 ng/mL) an
EC50 of 20.3 ng/mL is obtained.
Mefloquine
Out of 216 isolates, 124 satisfied the prespecified criteria
and for these the EC50 values have a log-normal distribu-
tion (p = 0.366), log(EC50) ~ N(3.68, 0.633) (Table 1). In
the highest concentration interval (115–230 ng/mL) an
EC50 of 137.8 ng/mL was calculated.
Chloroquine
Out of 183 samples, 117 satisfied the criteria and for them
log(EC50) ~ N(4.9, 0.680), p = 0.076 (Table 1). In the
highest concentration interval (341.5–683 ng/mL) EC50
of 420.4 ng/mL was obtained.
In Table 5 Bayesian EC50 estimates (c) are compared with
the standard estimates obtained using WinNonlin® (b).
The standard method oversestimated the EC50 of the most
resistant isolate by between 15% (artesunate) and 43%
(mefloquine).
Discussion
Antimalarial drug resistance is widely monitored using in-
vitro susceptibility testing. There are sentinel sites
throughout the malaria affected world monitoring for
drug resistance. A variety of methods have been developed
and the results have provided valuable information in the
assessment and mapping of antimalarial drug resistance
[7]. Evaluation of stored isolates in reference centres
allows proper standardisation of methodologies and
repeated tests on single isolates. But most of this testing in
the field is a "one-off" microtest on freshly obtained
blood samples. When antimalarial drug susceptibility
tests are reported the highest observed values observed are
naturally of greatest interest as they may represent emerg-
ing drug resistance. Drug regimens should aim to cure all
infections, and thus provide concentrations exceeding the
inhibitory concentrations for the most resistant prevalent
parasites. If only a single concentration range is evaluated
in an in-vitro susceptibility assay using serial dilutions
Table 1: Estimated distribution of EC50 values
Drug Mean1 SD1 N (%)2 P-value3
Artesunate 0.75 0.888 89 (47) 0.074
Halofantrine 1.84 0.979 85 (44) 0.100
Mefloquine 3.68 0.633 124 (58) 0.366
Chloroquine 4.9 0.680 117 (64) 0.076
1 mean and SD after the log-transformation
2 number of isolates which contributed to the estimation of the distribution
3 Kolmogorov-Smirnov test for normalityMalaria Journal 2007, 6:4 http://www.malariajournal.com/content/6/1/4
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then, by definition, the true EC50 of the most resistant iso-
lates must lie above or between the largest concentration
differences tested. Thus, unless the parasites are retested
with a higher concentration range (which they usually
cannot be), the precision of the estimated EC50 or EC90
value of the most resistant isolate will usually be the poor-
est of all the isolates assayed. Furthermore as curve fitting
or probit analysis takes no account of other isolates in the
series tested, then if there are two adjacent points with
extremely different values (often zero and 100% inhibi-
tion), a curve will be fitted as lying symmetrically between
the two. The EC50 will be assessed as lying close to the
mid-point between the two concentrations (Figure 2). But
if the parasites can be shown to derive from a single distri-
bution of susceptibilities, and this proviso is critical, the
prior probability is that the true EC50 value lies closer to
the population mean value. Thus resistance is systemati-
cally overestimated. A better estimate is provided by the
simple Bayesian analysis described above. Such a contin-
uum conforming to a single distribution of susceptibili-
ties is observed commonly for artesunate,
dihydroartemisinin, artemether, artemisinin, chloro-
quine, desethylamodiaquine, quinine, quinidine, lume-
fantrine, piperaquine, pyronaridine and mefloquine. For
example, the artesunate-mefloquine combination has
been systematically deployed for over twelve years on the
north-western border of Thailand. It has been reported in
studies of antimalarial susceptibility that the most resist-
ant isolate EC50 values were 23.4 ng/mL for artesunate and
197 ng/mL for mefloquine. Reanalysis of the data using
the Bayesian approach reduces this to 20.3 (15% less) ng/
mL for artesunate and 138 ng/mL (43% less) for meflo-
quine. When antimalarial drug resistance is reported pre-
cise details of the concentration range tested and the
analytical procedure used should always be provided.
For those resistance mechanisms in which single muta-
tions confer large reductions in susceptibility, such as the
Pfdhfr 164 mutation for pyrimethamine resistance or cyt b
268 mutations for atovaquone resistance there will clearly
be discontinuous distributions of susceptibility and this
method will not be appropriate. This emphasizes the
importance of distributional assessments before using
this Bayesian approach to analysis. Of course if parasites
can be cryopreserved then the resistant parasites dose-
response measurements should be repeated with selection
of higher concentrations covering the likely EC50 region.
For freshly assayed isolates this will not be possible as the
level of susceptibility is not known before the test. In this
case a Bayesian adjustment should be made for extreme
values if justified by the distributional assessment.
Conclusion
Conventional analytical methods for characterizing in-
vitro antimalarial drug susceptibility assess each isolate
independently and, consequently, overestimate the EC50
and EC90 for the most resistant isolates. Bayesian methods
based on the distribution of EC50 values in the whole
series offer considerable improvement of the estimate.
The method which is proposed here, does not require
Table 2: Parameter estimates obtained from fitting the 3-parameter sigmoid curve to the most resistant isolates using standard 
individual data analysis (fitted using WinNonlin®).
Isolate Parameter estimates (% CV)
EC50 γ Emax EC50*
Artesunate (A) 23.3(22) 12.5(65) 0.95 (2) 23.4 (12)
Halofantrine (B) 51.8(51564) 27.9 (225370) 1.10 (5) 50.1 (37)
Mefloquine (C) 195 (4160) 21.1 (25309) 1.15 (2) 175 (17)
Mefloquine (D) 197 (2014) 17.1 (12967) 1.25 (6) 178 (52)
Chloroquine (E) 1065 (18) 7.98 (68) 0.79 (4.2) 1065 (18)
Chloroquine (F) 536 (6) 3.5 (18) 0.92 (2.4) 536 (6)
* – estimates obtained by fitting model with boundary (-10,10) for γ
Table 3: Parameter estimates obtained from fitting the 3-parameter sigmoid curve to the data presented in the example using a 
Bayesian approach (Gibbs sampling) (fitted using WinBUGS®)
Isolate Posterior Parameter Estimates – median (95% range)
EC50 γ Emax
Artesunate (A) 21.3 (17.5 – 30.5) 59.7 (14.0 – 98.1) 0.95 (0.91 – 0.99)
Halofantrine (B) 43.7 (34.8 – 61.0) 61.3 (15.3 – 98.0) 1.09(1.00 – 1.19)
Mefloquine (C) 154 (123 – 215) 61.8 (16.2 – 98.2) 1.5(1.10 – 1.20)
Mefloquine (D) 150 (119 – 217) 57.0 (9.85 – 97.9) 1.25 (1.09 – 1.40)
Chloroquine (E) 873 (710 – 1294) 42.6 (6.2 – 78.2) 0.78 (0.71 – 0.85)
Chloroquine (F) 540 (461 – 673) 3.75 (2.52 – 55.2) 0.92 (0.88 – 0.97)Malaria Journal 2007, 6:4 http://www.malariajournal.com/content/6/1/4
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sophisticated software, nor does it make any assumptions
about the dose-response relationship, and it provides
more realistic estimates of the most resistant isolates' EC50
values
List of abbreviations
Emax; the maximum effect -usually refers to maximum
inhibition of growth or substrate uptake or synthesis in an
antimalarial drug susceptibility test
EC50; the concentration which results in 50% of the Emax
EC90 ; the concentration which results in 90% of the Emax
γ; The slope of the linear portion of the usually sigmoid
concentration effect relationship
Authors' contributions
KS, KC, AB, ND, NW contributed to the conceptualization
and writing of the paper. AB conducted the in-vitro sus-
ceptibility tests. All authors read and approved the final
manuscript.
Appendix I
Useful facts :
1. If f(x) is a density function for random variable x then
F(z) = P(x<z) =  ;  ;
P(a<x<b) = F(b)-F(a)
where P(x<z) denotes probability that random variable x
is less then z.
2. f(x) = 1/(σπ )·exp(-(x-µ)2/2σ2) density function for
N(µ, σ)
3. f(x) = 1/( π)·exp(-x2/2) density function for N(0,1)
4. Φ(x) = 1/( π) 
5. If x is random variable with distribution N(µ, σ) then
F(x) = Φ((x-µ)/σ))
Appendix II
1. Let assume x is N(µ, σ) with density function f(x) (as in
point 2, Appendix I)
2. We want to find median value of x in the interval (a,b)
3. We need to define density function g(x) such that:
fx d x
z
()
−∞ ∫ fx d x ()
−∞
∞
∫
2
2
2 exp(-x /2) dx 2 z
−∞ ∫
gx
if x a
Af x if x in interval a b and g x  dx
i
() () (,) () . =
<=
=
−∞
∞
∫
0
1
0f f x b >=






Table 4: Estimates of EC50 obtained from fitting the 3-parameter sigmoid curve to the data presented in the Example using WinBUGS, 
with upper boundary of γ set to 30 or 50.
Isolate Posterior Estimate of EC50 – median (95% range)
γ = 30 γ = 50
Artesunate (A) 22.2 (18.6 – 28.2) 21.9 (18.0 – 29.8)
Halofantrine (B) 46.5 (37.3 – 60.0) 45.2 (36.0 – 60.0)
Mefloquine (C) 165 (134 – 205) 161 (128 – 210)
Mefloquine (D) 157 (123 – 212) 153 (121 – 215)
Chloroquine (E) 913 (731 – 1260) 888 (719 – 1282)
Chloroquine (F) 539 (465 – 649) 540 (462 – 660)
Table 5: Methodological differences in the estimation of antimalarial resistance; the highest EC50 (ng/mL) (Brockman et al, 2000)
Isolate Range of concentrations tested (ng/mL) EC50 Standard estimate EC50 "Bayesian" estimate Overestimation by standard method (%)
Artesunate (A) 0.52 – 33.46 23.4 20.3 15%
Halofantrine (B) 1.02 – 65.32 51.8 41.2 26%
Mefloquine (C) 3.59 – 230 195 138 41%
Mefloquine (D) 3.59 – 230 197 138 43%
Chloroquine (E) 21.44 – 1,372 1065 801 32%
Chloroquine (F) 21.44 – 683 536 420 32%Publish with BioMed Central    and   every 
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 dx = A (Φ((b-µ)/σ)) - Φ((a-µ)/σ))) = 1
Therefore A = 1/(Φ((b-µ)/σ)) - Φ((a-µ)/σ))).
4. Median value of x in interval (a,b) is such a z that
G(z) = P(x<z) =   dx = 0.5
 dx = A   dx = A (Φ((z-µ)/σ)) - Φ((a-µ)/
σ))) =
(Φ((z-µ)/σ)) - Φ((a-µ)/σ)))/(Φ((b-µ)/σ)) - Φ((a-µ)/σ)))
= 0.5
After transformation we get:
Φ((z-µ)/σ) = (Φ((a-µ)/σ) + Φ((a-µ)/σ))/2
and
z = Φ-1 ((Φ((a-µ)/σ) + Φ((a-µ)/σ))/2)·σ + µ
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